TK-129 is a potent, orally effective, and low-toxicity KDM5B inhibitor (IC50 = 44 nM) with high affinity; it exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway; it reduces AngII-induced activation of cardiac fibroblasts in vitro and attenuates isoproterenol-induced myocardial remodeling and fibrosis in vivo; it can be used in the research of cardiovascular diseases.